,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2014-07-20 23:10:00,Boston Scientific Corporation ( BSX ) is scheduled to report its second-quarter 2014 results before the opening bell on Jul 24.,0.01680871844291687,0.009801377542316914,0.9733899235725403,neutral,0.0070073409005999565
1,2014-07-20 23:10:00,"Last quarter, the company had posted a positive earnings surprise of 11.11%.",0.9421554207801819,0.030489712953567505,0.027354910969734192,positive,0.911665678024292
2,2014-07-20 23:10:00,"Moreover, the four-quarter trailing average beat is pegged at 10.10%.",0.07111072540283203,0.03676873445510864,0.8921205997467041,neutral,0.03434199094772339
3,2014-07-20 23:10:00,Let's see how things are shaping up for this announcement.,0.04255152866244316,0.005616344977170229,0.951832115650177,neutral,0.03693518415093422
4,2014-07-20 23:10:00,"Amid challenging economic conditions, competitive environment, pressure on core segments and a larger-than-expected currency headwind, Boston Scientific posted mixed first-quarter 2014 results beating on earnings but missing revenues.",0.020023098215460777,0.9685158133506775,0.011461104266345501,negative,-0.948492705821991
5,2014-07-20 23:10:00,"At the same time, the company also provided its outlook for the second quarter.",0.03534606844186783,0.006237335037440062,0.9584165811538696,neutral,0.02910873293876648
6,2014-07-20 23:10:00,Boston Sientific expects adjusted earnings to remain in the band of 18-20 cents per share while revenues are projected in the range of $1.84-$1.89 billion.,0.21294349431991577,0.018433574587106705,0.7686229348182678,neutral,0.19450992345809937
7,2014-07-20 23:10:00,"In addition, gross margin will likely remain in the range of 70−71%.",0.11023236066102982,0.012722106650471687,0.8770455121994019,neutral,0.09751025587320328
8,2014-07-20 23:10:00,"Selling, general and administrative as well as research and development expense margins are expected to be within 36.5%−37.5%, and 11.5%−12%, respectively, resulting in a targeted operating margin of 19% to 20%.",0.14368952810764313,0.05324723571538925,0.8030632734298706,neutral,0.09044229239225388
9,2014-07-20 23:10:00,"Despite several initiatives undertaken by Boston Scientific to revive its top line, we remain cautious as core segments like Cardiac Rhythm Management (CRM) and drug-eluting stents (DES) continue to witness several headwinds.",0.07284495234489441,0.878020703792572,0.04913442209362984,negative,-0.80517578125
10,2014-07-20 23:10:00,The current challenging scenario fails to give any assurance that the size of the CRM and DES markets will increase above existing levels or the company will be able to increase its market share or net sales in these segments in the near term.,0.9275138974189758,0.017626803368330002,0.05485934391617775,positive,0.9098870754241943
11,2014-07-20 23:10:00,"Meanwhile, Boston Scientific is resorting to all available means in order to return to growth.",0.8079776167869568,0.015349227003753185,0.17667320370674133,positive,0.7926284074783325
12,2014-07-20 23:10:00,"To revive its top line, the company is focusing on strategic initiatives to drive growth and profitability.",0.9161504507064819,0.013134448789060116,0.07071511447429657,positive,0.9030160307884216
13,2014-07-20 23:10:00,"These include the recently announced restructuring initiatives, strengthening of the company's portfolio, targeting suitable acquisitions in areas of unmet medical needs, and focusing on emerging markets.",0.8020181655883789,0.010588335804641247,0.18739351630210876,positive,0.7914298176765442
14,2014-07-20 23:10:00,"Boston Scientific has a strong pipeline of products under development, the launch of which should drive the top line.",0.784264087677002,0.010443205013871193,0.20529265701770782,positive,0.7738208770751953
15,2014-07-20 23:10:00,"We are also encouraged by the focus on emerging markets, especially India and China.",0.6194201707839966,0.011570771224796772,0.36900901794433594,positive,0.6078494191169739
16,2014-07-20 23:10:00,Our proven model does not conclusively show that Boston Scientific is likely to beat earnings this quarter.,0.855976939201355,0.03318990767002106,0.11083322018384933,positive,0.8227870464324951
17,2014-07-20 23:10:00,"It is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 for this to happen.",0.3326624929904938,0.016127387061715126,0.6512101292610168,neutral,0.3165351152420044
18,2014-07-20 23:10:00,That is not the case here as you will see below.,0.017427746206521988,0.06175145506858826,0.9208208322525024,neutral,-0.04432370886206627
19,2014-07-20 23:10:00,"Zacks ESP: Boston Scientific's Earnings ESP is 0.00%, since both the Most Accurate estimate and the Zacks Consensus Estimate stand at 20 cents.",0.052821867167949677,0.5941957235336304,0.35298240184783936,negative,-0.5413738489151001
20,2014-07-20 23:10:00,"We caution against stocks with Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revision momentum.",0.06574495136737823,0.7677916288375854,0.16646340489387512,negative,-0.7020466923713684
21,2014-07-20 23:10:00,"Other Stocks to Consider

Here are three companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter:

Wright Medical Group Inc. ( WMGI ) has an earnings ESP of +2.22% and a Zacks Rank #1 (Strong Buy).",0.6029447913169861,0.013505633920431137,0.3835495710372925,positive,0.5894391536712646
22,2014-07-20 23:10:00,Wright Medical will be reporting second-quarter earnings on Aug 5.,0.017558757215738297,0.012035739608108997,0.9704054594039917,neutral,0.005523017607629299
23,2014-07-20 23:10:00,Hospira Inc. ( HSP ) has an earnings ESP of +1.79% and a Zacks Rank #2 (Buy).,0.35419607162475586,0.015041261911392212,0.6307626366615295,neutral,0.33915480971336365
24,2014-07-20 23:10:00,Hospira will report second-quarter earnings on Jul 30.,0.023448320105671883,0.010195276699960232,0.9663563370704651,neutral,0.01325304340571165
25,2014-07-20 23:10:00,"Community Health Systems, Inc. ( CYH ) has an earnings ESP of +2.94% and a Zacks Rank #3 (Hold).",0.20149001479148865,0.014479084871709347,0.7840309143066406,neutral,0.18701092898845673
26,2014-07-20 23:10:00,Community Health will be reporting second-quarter earnings on Aug 1.,0.0211305171251297,0.010962994769215584,0.9679064154624939,neutral,0.010167522355914116
27,2014-07-20 23:10:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
28,2014-07-20 23:10:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
29,2014-07-20 23:10:00,"Click to get this free report

To read this article on Zacks.com click here.",0.020684564486145973,0.03315984085202217,0.9461556077003479,neutral,-0.012475276365876198
30,2014-07-20 23:10:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
